a target of 120.00 Feb.2016 this is what i come up with,,,,,,,,fyi just my own findings..do you own dd
IF YOU REALLY HAD DONE YOUR RESEARCH YOU WOULD KNOW THAT WAS FOOLISH TO SAY.
Sep 23, 2013 - Last Friday, an early top-line Phase III data release for Duchenne Muscular ... of drisapersen is GlaxoSmithKline (GSK) - and fortunately for GSK ... In addition to this, we note that the toxicity remains a serious issue
Comparison or competition ...sarepta is the only real drug option for dmd worth while and shame on biomarin for even trying to long term dose with their drug/
It is always good not to argue with the boss.It is always wise to stop all the dmd parent involvements while meetings are being done...fyi
Most of them do not have a real clue on the price target '' a few here have 100 times more knowledge than any of the analyst do. Just watch the next 6 months here it will tell all
Will not matter if they are approved ''biomarin'' /once sarepta is approved all will jump ship to get sarepta's drug . Real simple ..biomarin has a toxic drug that should not be used for long term dosing and has a very small effect if any..
many have opinions based on motives or guessing mine are based on facts and research.
Sarepta has so much room to grow and i see a big under value here. The real facts are this'' Sarepta really has the only real worth while treatment for dmd and it is the first in history.
just look at the posts of desperation and see.......
cover boys..or pay much much more.